19:51 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) on Dec. 18 in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing...
22:57 , Dec 18, 2018 |  BC Extra  |  Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing to begin "formal"...
15:59 , Nov 16, 2018 |  BC Week In Review  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
00:26 , Nov 16, 2018 |  BC Extra  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
19:25 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Patient sample, cell culture, mouse and rat studies suggest inhibiting ENO1 could help treat pulmonary arterial hypertension (PAH) associated with other conditions. In pulmonary artery smooth muscle cell samples from patients with PAH...
16:36 , Sep 21, 2018 |  BC Week In Review  |  Company News

United gets rights to Samumed's IPF compound

Samumed LLC (San Diego, Calif.) granted United Therapeutics Corp. (NASDAQ:UTHR) exclusive, U.S. and Canadian rights to idiopathic pulmonary fibrosis candidate SM04646, a Wnt signaling pathway inhibitor. Samumed will receive $10 million up front, and is...
22:02 , Sep 17, 2018 |  BC Extra  |  Company News

United gets rights to Samumed's IPF compound

Samumed LLC (San Diego, Calif.) granted United Therapeutics Corp. (NASDAQ:UTHR) exclusive, U.S. and Canadian rights to idiopathic pulmonary fibrosis candidate SM04646, a Wnt signaling pathway inhibitor. Samumed will receive $10 million up front, and is...
17:36 , Sep 7, 2018 |  BC Week In Review  |  Company News

MannKind stock climbs after closing treprostinil deal with United Therapeutics

MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) shot up $0.98 (89%) to $2.08. on Sept. 4 after signing a deal with United Therapeutics Corp. (NASDAQ:UTHR) for rights to Treprostinil Technosphere. MannKind will receive $45 million up front...
01:40 , Aug 18, 2018 |  BioCentury  |  Regulation

Pediatric push

FDA has endorsed extrapolation of therapeutic efficacy from adults to children for new drugs to treat partial onset seizures in a draft guidance and is now discussing in public meetings whether the approach can be...
03:14 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

United Therapeutics' Orenitram delays disease progression in Phase III for PAH

United Therapeutics Corp. (NASDAQ:UTHR) said Orenitram treprostinil met the primary endpoint in the double-blind, international Phase III FREEDOM-EV trial in 690 pulmonary arterial hypertension (PAH) patients on background oral monotherapy. Thrice-daily oral Orenitram significantly delayed...